CA2560080A1 — Solifenacin-containing composition
Assigned to Astellas Pharma Inc · Expires 2005-09-22 · 21y expired
What this patent protects
A novel process for producing a composition containing either solifenacin or a salt thereof; and a composition containing either solifenacin or a salt thereof obtained by the production process, which contains a solifenacin compound having an optionally substituted lower alkyl bo…
USPTO Abstract
A novel process for producing a composition containing either solifenacin or a salt thereof; and a composition containing either solifenacin or a salt thereof obtained by the production process, which contains a solifenacin compound having an optionally substituted lower alkyl bonded to the 2-position of the quinuclidine. The composition contains solifenacin in a high purity, and contains, only in an extremely small amount, unexpected compounds which are peculiar to the production process. It hence has extremely preferable properties required of ingredients for medicines.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.